AstraZeneca has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former’s efforts to grow its cell therapies business.

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China. Under the deal, AstraZeneca will enter ...

WILMINGTON, DE — Groundbreaking results from AstraZeneca’s Phase III SERENA-6 trial reveal a significant leap forward in the treatment of hormone receptor (HR)-positive, HER2-negative advanced ...

AstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as the company tries to grab a slice of the booming weight-loss market and aims to almost double ...

AstraZeneca has admitted in court documents that its COVID-19 vaccine could cause a rare but deadly blood-clotting condition, potentially exposing the UK pharmaceutical giant to tens of millions ...

Drawn up syringes containing the AstraZeneca COVID-19 vaccines and the empty vial are seen in a tray at the Claremont Showgrounds Covid-19 Vaccination Clinic on May 03, 2021 in Perth, Australia.

AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory ...

AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes—the latest pharmaceutical firm to bet on treatment similar to popular weight ...

AstraZeneca Plc agreed to buy Icosavax Inc. for as much as $1.1 billion to gain a developer of innovative vaccines for respiratory viruses.

AstraZeneca will cap inhaler costs at $35 per month. The cost-reduction strategy follows a similar move from Boehringer Ingelheim, a rival in the medical device sector. March 18, 2024.

AstraZeneca has opened its first U.S.-operated cell therapy manufacturing plant in Rockville, Maryland, as part of its ongoing $3.5 billion investment in American innovation.

A Utah mother who says she was “permanently disabled” after taking part in the US clinical trial of AstraZeneca’s COVID-19 vaccine is suing the drug manufacturer because it failed to cough ...